Sat Oct 11 03:41:08 UTC 2025: Okay, here’s a news article summarizing the provided text, written from an Indian perspective, suitable for publication in *The Hindu*:
**The Hindu: World Affairs**
**Trump Secures Drug Price Cuts in U.S., AstraZeneca Announces Major Investment Amidst Tariff Threats**
**Washington D.C. | October 11, 2025** – In a move hailed as a victory for American consumers, President Donald Trump has announced a deal with AstraZeneca to lower prescription drug prices for Medicaid, following a similar agreement with Pfizer last month. The announcement, made in the Oval Office alongside AstraZeneca CEO Pascal Soriot, marks a significant step in the Trump administration’s efforts to tackle high drug costs in the United States.
Under the agreement, AstraZeneca will offer “most-favoured-nation” pricing to Medicaid, mirroring the lowest prices offered in other developed countries, and guaranteeing these rates on newly launched medications. Trump stated that this could result in Americans paying the lowest prices globally.
The announcement comes after Trump threatened steep tariffs against pharmaceutical companies. The pressure seemingly worked, with Soriot admitting that negotiations with Trump and his team had been challenging.
This development follows an executive order signed by President Trump in May, setting a deadline for drugmakers to voluntarily reduce prices or face new government limits on reimbursement.
AstraZeneca, a Cambridge, UK-based company with a strong portfolio of cancer treatments like Tagrisso and Lynparza, also announced a $4.5 billion investment in a new manufacturing plant near Charlottesville, Virginia. This investment is part of a broader plan to invest $50 billion in the U.S. by 2030, aiming to generate $80 billion in total revenue, half of which will be generated in the United States. Trump predicted that the investment could lead to 3,600 jobs domestically.
While one of AstraZeneca’s drugs was already subject to price reductions due to a Medicare negotiating strategy implemented under President Biden, Trump insisted Democrats shouldn’t get credit.
As part of its broader strategy, the Trump administration is launching TrumpRX.gov, a website slated to launch in January 2026, where Americans can purchase drugs directly from manufacturers. Both Pfizer and AstraZeneca are expected to participate in this initiative. The website is being designed by The National Design Studio, led by Airbnb co-founder Joe Gebbia.
**Indian Perspective:**
This move by the Trump administration and AstraZeneca could have broader implications for the global pharmaceutical landscape, including India. While the immediate impact is on the U.S. market, the adoption of “most-favoured-nation” pricing raises questions about pricing strategies in other countries. Indian pharmaceutical companies, many of which supply generic medications to the U.S., will be closely watching these developments and how they might influence future pricing negotiations and trade relationships. Furthermore, AstraZeneca’s substantial investment in the U.S. could potentially impact its investment decisions in other regions, including India, though it’s too early to gauge those effects.
First Piper 